Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need.
Saved in:
| Title: | Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need. |
|---|---|
| Authors: | Yasinskaya Y; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Bala S; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Waack U; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Dixon C; Division of Biometrics IV, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration ; Silver Spring, Maryland, USA., Higgins K; Division of Biometrics IV, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration ; Silver Spring, Maryland, USA., Moore JN; Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration ; Silver Spring, Maryland, USA., Jjingo CJ; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., O'Shaughnessy E; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Colangelo P; Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration ; Silver Spring, Maryland, USA., Botgros R; Health Threats and Vaccines Strategy, European Medicines Agency, Amsterdam, the Netherlands., Nambiar S; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Angulo D; Scynexis, Jersey City, New Jersey, USA., Dane A; DaneStat Consulting, Macclesfield, United Kingdom., Chiller T; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Hodges MR; RNA Medicines, San Diego, California, USA., Sandison T; Cidara Therapeutics, San Diego, California, USA., Hope W; Centre for Excellence in Infectious Diseases Research, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Walsh TJ; Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York, New York, USA., Pappas P; Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA., Katragkou A; Transplantation-Oncology Infectious Disease Program, Weill Cornell Medicine, New York, New York, USA., Kovanda L; Astellas Pharma Global Development, Northbrook, Illinois, USA., Rex JH; F2G, Manchester, United Kingdom., Marr KA; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA., Ostrosky-Zeichner L; Director of the Laboratory of Mycology Research, McGovern Medical School, Houston, Texas, USA., Sekine S; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Deshpande M; DRT Strategies, Arlington, Virginia, USA., Shukla SJ; Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Farley J; Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Aug 14; Vol. 77 (3), pp. 380-387. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciad195 |
